Alessia Romagnoli*, Fiorenzo Santoleri and Alberto Costantini Pages 1-8 (8)
Objective: The objective of this study is to evaluate adherence, persistence and switching of antipsychotics and compare in real life long-acting with oral formulations.
Materials and methods: This pharmacological, observational, retrospective, non-interventional study involved all patients of the ASL of Pescara treated in the front-line with AP in the period between January 2011 and February 2019. Adherence was measured using the ratio between received daily dose and prescribed daily dose. Persistence to treatment with antipsychotics was calculated as the daily difference between start and end of treatment.
Results: We examined 840 patients treated with Aripiprazole, 130 patients treated with Paliperidone and 925 patients treated with Risperidone. Adherence was significantly better in long-acting formulations with values of 0.89 (Aripiprazole) and 0.82 (Paliperidone and Risperidone) than in oral formulations with values of 0.78, 0.70 and 0.58, respectively. Persistence curves over three years of therapy have not shown a statistically significant difference (p = 0.3314). Persistence curves based on formulation have not shown a statistically significant difference. 7% of patients treated with Aripiprazole, 12% of patients treated with Risperidone and 28% of patients treated with Paliperidone switched therapy.
Conclusions: In all drugs of the present study, adherence values were better in LAI than in OA, whereas no statistically significant difference was found in persistence values.
antipsychotics, adherence, persistence, real life, long-acting injectable drugs, oral antipsychotics
ASL Pescara General Hospital, Hospital Pharmacy, Renato Paolini 47, ASL Pescara General Hospital, Hospital Pharmacy, Renato Paolini 47, ASL Pescara General Hospital, Hospital Pharmacy, Renato Paolini 47